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Background: Advanced glycation end products (AGE)-receptor for AGE (RAGE) axis and renin-angiotensin system
(RAS) play a role in diabetic nephropathy (DN). Matrix metalloproteinase-2 (MMP-2) activation also contributes to
DN. However, the pathological interaction among AGE-RAGE, RAS and MMP-2 in DN remains unknown. We examined
here the involvement of AGE and RAS in MMP-2 activation in streptozotocin (STZ)-induced diabetic rats and in
AGE-exposed rat renal proximal tubular cells (RPTCs).
Methods: Experimental diabetes was induced in 6-week-old male Sprague–Dawley (SD) rats by intravenous injection
of STZ. Diabetic rats received ramipril (3 mg/kg body weight/day) or vehicle for 32 weeks. AGE-modified rat serum
albumin (AGE-RSA) or RSA was intraperitoneally administrated to 6-week-old male SD rats for 16 weeks. RPTCs were
stimulated with 100 μg/ml AGE-modified bovine serum albumin (AGE-BSA) or BSA in the presence or absence of 10−7 M
ramiprilat, an inhibitor of angiotensin-converting enzyme or 100 nM BAY11-7082, an IκB-α phosphorylation inhibitor.
Results: AGE and RAGE expression levels and MMP-2 activity in the tubules of diabetic rats was significantly increased in
association with increased albuminuria, all of which were blocked by ramipril. AGE infusion induced tubular MMP-2
activation and RAGE gene expression in SD rats. Ramiprilat or BAY11-7082 inhibited the AGE-induced MMP-2
activation or reactive oxygen species generation in RPTCs. Angiotensin II increased MMP-2 gene expression in
RPTCs, which was blocked by BAY11-7082.
Conclusions: Our present study suggests the involvement of AGE-RAGE-induced, RAS-mediated MMP-2 activation in
experimental DN. Blockade of AGE-RAGE axis by ramipril may protect against DN partly via suppression of MMP-2.
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Diabetic nephropathy (DN) is a leading cause of end-
stage renal disease, which could account for disability
and high mortality rate in patients with diabetes [1,2].
The development and progression of DN are character-
ized by glomerular hypertrophy and inflammatory cell
infiltration, followed by extracellular matrix (ECM) accu-
mulation in mesangial area and an increased albumin ex-
cretion rate [3]. Diabetic nephropathy ultimately progresses* Correspondence: fukami@med.kurume-u.ac.jp
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However, it has recently been recognized that changes
within tubulointerstitium are more important than glomer-
ulopathy in terms of renal dysfunction in DN [5,6].
Reducing sugars can react non-enzymatically with the
amino groups of proteins to initiate a complex series of
rearrangements and dehydrations, and then to produce a
class of irreversibly cross-linked moieties termed ad-
vanced glycation end products (AGE) [7-9]. The forma-
tion and accumulation of AGE in various tissues have
been shown to progress at an accelerated rate under hyper-
glycemic conditions [10-12]. There is accumulating evi-
dence that AGE and receptor for AGE (RAGE) interaction
induces oxidative stress generation and subsequentlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fukami et al. Diabetology & Metabolic Syndrome 2014, 6:86 Page 2 of 9
http://www.dmsjournal.com/content/6/1/86evokes inflammatory reactions, thereby causing pro-
gressive alteration in renal architecture and loss of
renal function in diabetes [13-15].
Matrix metalloproteinases (MMPs) are a family of
zinc-dependent endopeptidases comprising more than
20 members that can degrade numerous types of ECM
components [16]. Among various MMPs, MMP-2 has
attracted great attention because it can degrade type-I
and -IV collagen and laminin, major components of
tubular basement membrane and interstitium [17,18].
Recently, we have found that serum MMP-2 levels are
one of the independent determinants of proteinuria in
patients with chronic kidney disease [19]. Further, plasma
MMP-2 levels and its activity are significantly higher in
type-1 diabetic patients compared with control subjects
[20], and urinary MMP-2 values are positively associated
with renal hyperfiltration and albuminuria in these dia-
betic patients as well [20]. In addition, in animal models,
MMP-2 has been shown to induce renal tubular cell
epithelial-mesenchymal transformation, which could
cause tubulointerstitial fibrosis in diabetic nephropathy
[21,22]. These observations suggest the involvement of
MMP-2 activation in albuminuria and tubulointerstitial
injury of diabetic nephropathy [23].
There is accumulating evidence to show the active par-
ticipation of renin-angiotensin system (RAS) in DN as
well [24]. Indeed, inhibition of RAS by angiotensin-
converting enzyme (ACE) inhibitor or angiotensin II
(Ang II) type-1 receptor (AT1R) blocker has been shown
to suppress the development and progression of ne-
phropathy in both type-1 and type-2 diabetic subjects
[25,26]. Further, losartan, an AT1R blocker, improves
renal outcome in patients with type-2 diabetes [27].
Moreover, we have previously found that RAS blockers
could inhibit the AGE-elicited mesangial cell hyper-
trophy, proximal tubular cell injury, and podocyte DNA
damage and detachment in vitro [28-30]. However, the
involvement of AGE and RAS in MMP-2 activation in
DN remains unknown. Therefore, we first examined the
effects of ramipril, an inhibitor of ACE on MMP-2 activ-
ity, AGE and RAGE expression in renal tubules of strepto-
zotocin (STZ)-induced diabetic rats. Then we investigated
whether AGE injection could stimulate RAGE gene ex-
pression and MMP-2 activity in tublules of normal non-
diabetic rats. We further studied the effects of ramiprilat,
an active metabolite of ramipril, on MMP-2 activity and re-
active oxygen species (ROS) generation in AGE-exposed
rat renal proximal tubular cells (RPTCs).
Methods
Experimental animal models
Experimental diabetes was induced in 6-week-old male
Sprague–Dawley (SD) rats (200–250 g) by intravenous
injection of STZ (50 mg/kg body weight) in sodiumcitrate buffer pH 4.5, following an overnight fast [31].
Rats with plasma glucose concentrations in excess of
15 mmol/L were included in this study. Vehicle-injected
control (Ctrl) animals (n = 15) were followed concur-
rently. Diabetic rats were randomized into two groups
and followed for 32 weeks; one group (n = 15) received a
vehicle, and the other an ACE inhibitor, ramipril (1 mg/kg
body weight/day in drinking water; generously provided
by Sanofi, Bridgewater, NJ) for 32 weeks (n = 16) [32].
Two units of ultralente insulin (Ultratard HM, Novo In-
dustries, Bagsvaerd, Denmark) were administrated daily to
diabetic animals to prevent ketoacidosis and avoid death.
In addition, non-diabetic normal male SD rats (6-week-
old) were infused intraperitoneally with AGE-modified rat
serum albumin (AGE-RSA) (n = 10) or RSA (n = 9) at a
dose of 20 mg/kg body weight/day for 16 weeks by an os-
motic pump (Alzet osmotic pumps, model 1004, Cupertino,
CA, USA).
Systolic blood pressure (SBP) was measured by tail-cuff
plethysmography as described previously [33]. Glomerular
filtration rate (GFR) was evaluated by 99Tc-DTPA, and
urinary albumin excretion (UAE) levels by an enzyme-
linked immunosorbent assay (ELISA) kit (Bethyl Labora-
tories, Montgomery, TX, USA). Other clinical valuables
were measured as described previously [31]. All animal
procedures were in accordance with guidelines set by the
Baker IDI Heart and Diabetes Institute Ethics Committee
and the National Health and Medical Research Council of
Australia.
Preparation of AGE-RSA and AGE-modified bovine serum
albumin (AGE-BSA)
AGE-RSA and AGE-BSA were prepared by incubating
RSA or BSA (Fraction V, Sigma Chemical Co, St. Louis,
MO, USA) with 0.5 M D-glucose in PBS at 37°C for
3 months as previously described [34]. After sterilization
using 0.2 μm micropore filters, unincorporated glucose was
removed by dialysis against phosphate buffer saline (PBS) at
4°C for 48 hr. Samples were passed through Detoxigel col-
umn (Pierce Biotechnology Inc., Rockford, IL, USA) in order
to remove endotoxin. Preparations were tested for endo-
toxin using Limulus Amebocyte Lysate validity testing
(AMS Laboratories, Sydney, Australia); no endotoxin was
detected. Finally, the solution was filtered through 0.2 μm
micropore filter in sterile conditions, and percentage of ly-
sine modifications and carboxymethyllysine (CML) moieties
were determined by Selective Ion Monitoring Gas chroma-
tography–mass spectrometry as previously described [35].
Control non-glycated RSA or BSA was incubated in the
same conditions except for the absence of glucose.
Isolation of renal tubules from kidneys
The cortical tissue was minced and gently pushed
through a 250 μm steinless steel mesh with 0.9% sodium
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and 75 μm meshes. The tubules were collected on the
125 μm mesh as described previously [36]. Tubular
structures were confirmed by light microscopy. After
centrifugation, the tubules were re-suspended in the lysis
buffer (50 mM Tris–HCl, 150 mM NaCl, 0.02% sodium
azide, 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxy-
cholate) containing a complete protease inhibitor cocktail
(Roche Molecular Biochemicals, Mannheim, Germany)
without ethylenediaminetetraacetic acid (EDTA). Then
the samples were sonicated and the protein concentration
was measured using a BCA protein assay kit (Pierce
Biotechnology Inc.).
Gelatin zymography
Twenty μg protein isolated from renal tubules or cell
culture media were separated by 8% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
containing 1 mg/ml gelatin (Labchem, Auburn, NSW,
Australia), and active MMP-2 levels were evaluated by
zymography as previously described [14].
Measurement of AGE levels in tubules
AGE levels in the isolated tubules were measured with
CML ELISA system as previously described [37]. In
brief, 1 μg of samples diluted in 50 mM carbonate buffer
(pH 9.6) (1:800) or standards were added to a microtitre
plate (Nunc-Immuno MaxiSorp, Nunc, Kamstrup, Ros-
kilde, Denmark) and incubated overnight at 4°C. After
washing three times with PBS (pH 7.4) containing 0.1%
Tween-20, wells were blocked for 1 hr with PBS con-
taining 1% BSA, and then 100 μl of a rabbit polyclonal
anti-CML antibody (5 μg/ml) was added [38]. After 1 hr
incubation and washing, 100 μl of 0.2 μg/ml goat-anti-
rabbit IgG biotinylated antibody (Dako Corporation,
Carpinteria, CA, USA) was added to each well. After
1 hr of shaking, wells were washed and 100 μl of strepta-
vidin horseradish peroxidase (Dako Corporation) was
added for 30 min. The wells were washed and 100 μl of
Tetramethylbenzidine (Sigma Chemical Co.) was added,
the reaction being terminated after 15 min using 100 μl
1.8 M H2SO4. The absorbance was quantitated using a
microtitre plate reader at 450 nm (EMax, Molecular De-
vices Corporation, Sunnyvale, CA, USA).
Western blot analysis
Ten μg protein isolated from renal tubules was separated
by 10% SDS-PAGE electrophoresis, and then transferred
to a polyvinylidene fluoride membrane (Hybond P;
Amersham, Buckinghamshire, UK). Membranes were in-
cubated with mouse anti-RAGE (1:1000) or rabbit anti-
α-tubulin (1:1000) antibodies overnight, and then the
secondary antibody horseradish peroxidase-conjugated
mouse or rabbit IgG for 1 hr. Bound antibodies weredetected by reaction with an enhanced chemilumines-
cence kit (Pierce Biotechnology Inc.). All antibodies were
obtained from Chemicon (Santa Cruz, SA, USA).
Quantitative real-time reverse-transcription polymerase
chain reaction (RT-PCR)
About 4 μg of total RNA extracted from each kidney
cortex or RPTCs were used to synthesize cDNA with
the SuperScript First-Strand Synthesis System for RT-
PCR (Invitrogen, Carlsband, CA, USA) as previously de-
scribed [35]. Quantitative real-time RT-PCR was performed
using Assay-on-Demand and TaqMan 5 fluorogenic nucle-
ase chemistry (Applied Biosystems, Foster City, CA, USA)
according to the supplier’s recommendation. The forward,
reverse primers and specific probes for rat RAGE and
MMP-2 genes were 5′-TCCTGGTGGGACCGTGAC-3′,
5′-GGGTGTGCCATCTTTTATCCA-3′, and FAM5′-TG
TGCCATCTCTGC-3′-MGB, and 5′-GCCCCTATCTACA
CCTACACCAA-3′, 5′-TGGATCCCCTTGATGTCAT
CA-3′, and FAM-5′-AACTTCCGATTATCCC-3′-MGB, re-
spectively. TaqMan Ribosomal RNA Control Reagents (18S)
was used as an endogenous control (Applied Biosystems).
Isolation and characterization of RPTCs
RPTCs were isolated from rat kidney as previously de-
scribed [39]. In brief, kidneys were removed from male
SD rats (200–250 g), and renal cortex was minced and
centrifuged at 250 g, 4°C for 5 min. Final pellets were
digested in Dulbecco’s Modified Eagle’s Medium/Ham’s
F12 (1:1) containing 1 mg/mL collagenase (Type-2,
Worthington Biochemical Corporation, Lakewood, NJ,
USA) for 30 min at 37°C with constant agitation. This
suspension was filtered through a 75 μm pore size
metal sieve to remove glomeruli, and re-suspended in
a 50% Percoll solution (Sigma-Aldrich Chemie GmbH,
Buchs, Switzerland) followed by centrifugation at 26,500 g
at 4°C for 30 min. The lowest band was retrieved as it is
enriched for proximal tubule fragments at a purity of
greater than 98% as described previously [40]. RPTCs
were characterized as cobble stone-like appearance and
immunocytochemical characteristics with positive staining
for cytokeratin and P. vulgaris lectin in the absence of
CD90.1 (thy1.1) using confocal microscopy. Treatments
with AGE-BSA, Ang II (Sigma Chemical Co.), an inhibitor
of ACE, ramiprilat, or an inhibitor of IκB-α phosphoryl-
ation, BAY11-7082 ((E)-3-(4-methylphenylsulfonyl)-2-pro-
penenitrile) (Biomol international, Lp, USA) [41] were
carried out in Minimum Essential Medium containing D-
valine instead of L-valine without fetal calf serum in hu-
midified 5% CO2/95% air atmosphere at 37°C.
Intracellular ROS generation
RPTCs were treated with 100 μg/ml AGE-BSA or BSA
in the presence or absence of 10−7 M ramiprilat for
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sured using the fluorescent probe 5,6-chloromethyl-
2′,7′-dichlorohydrofluorescein diacetate (Molecular Probes,
Eugene, OR, USA) as described previously [28].Statistical analysis
Results are expressed as mean ± standard error. Data for
albuminuria were not normally distributed, therefore an-
alyzed as logarithmic transformation. One-way ANOVA
followed by the Tukey-test or unpaired t-test was per-
formed for statistical comparisons; p < 0.05 was consid-
ered significant. All statistical analyses were performed
with SPSS system (Ver. 20, SPSS, Chicago, IL, USA).Results
Characteristics of animals
Compared with non-diabetic Ctrl rats, plasma glucose,
glycated hemoglobin (HbA1c), SBP, kidney-to-body weight
ratio, GFR and UAE levels were significantly higher in dia-
betic rats (p < 0.001) (Table 1). SBP was partially, but not
significantly, decreased after ramipril treatment (Table 1).
Furthermore, although plasma glucose, HbA1c or GFR
levels were not affected by the treatment with ramipril, it
significantly reduced the UAE levels in diabetic rats (p <
0.001) (Table 1).
Compared with RSA treatment, AGE-RSA injection
tended to increase UAE levels, but the effects were mod-
est, not significant (p = 0.13) (Table 1). In addition,
AGE-RSA injection did not affect any clinical parame-
ters in SD rats compared with RSA infusion.Ramipril decreased MMP-2 activity, AGE and RAGE
expression in the tubules of diabetic rats
As shown in Figure 1A-C, compared with Ctrl rats,
MMP-2 activity, AGE and RAGE expression levels in
the tubules of diabetic rats was significantly increased,
all of which were inhibited by the treatment with
ramipril.Table 1 Characteristics of animals
Ctrl DM
Number 15 15
Plasma glucose (mmol/L) 6.9 ± 095 33.2 ± 2.7*
%HbA1c (%) 5.5 ± 0.7 18.3 ± 2.6*
Systolic BP (mmHg) 114 ± 9 134 ± 13*
KW/BW ratio 5.3 ± 0.6 10.9 ± 1.5*
eGFR (ml/min) 6.7 ± 1.1 11.2 ± 1.4*
UAE (mg/24 h) 5.6 ± 4.3 53.9 ± 51.8*
Data are mean ± SEM. *p < 0.001 vs Ctrl, #p < 0.05 vs Ctrl, $p < 0.001 vs DM.
Abbreviation: Ctrl control, DM diabetes mellitus, RSA rat serum albumin, AGE-RSA ad
blood pressure, KW/BW ratio kidney-to-body weight ratio, GFR glomerular filtrationAGE-RSA infusion increased tubular MMP-2 activity and
RAGE gene expression in SD rats
We next investigated whether AGE-RSA could directly
induce MMP-2 activation in tubules. We evaluated
renal rather than tubular RAGE gene expression in the
present study because (1) tubules and interstitium
make up approximately 80-90% of the renal volume
and (2) isolation of tubules from the kidney cortex
might affect mRNA stability and expression level [42].
As shown in Figure 1D and E, compared with RSA-
infused rats, renal RAGE gene expression and tubular
MMP-2 activity were significantly increased in AGE-
RSA-infused rats.
Ramiprilat suppressed the AGE-elicited MMP-2 activation
and ROS generation in RPTCs
We examined whether and how AGE could induce
MMP-2 activation in vitro. Since AGE or Ang II exert
various biological effects via activation of redox-sensitive
transcription factor NF-κB, we studied the effects of
BAY11-7082, an inhibitor of NF-κB activation on AGE-
or Ang II-induced MMP-2 gene expression and activity
in PRTCs. Treatment with 100 μg/ml AGE-BSA signifi-
cantly increased active MMP-2 production by RPTCs,
which was completely prevented by 10−7 M ramiprilat or
100 nM BAY11-7082 (Figure 2A and B). Ramiprilat
completely blocked the AGE-induced ROS generation in
RPTCs, whereas 10−6 M Ang II significantly increased
MMP-2 gene expression, which was also inhibited by
BAY11-7082 (Figure 2C and D).
Discussion
In the present study, we demonstrated that (1) MMP-2
activity, AGE and RAGE expression levels were signifi-
cantly increased in renal tubules of diabetic rats, all of
which were blocked by the treatment with ramipril; (2)
UAE, a prognostic marker of DN, was increased in dia-
betic rats, which was also inhibited by ramipril; (3) AGE
injection significantly increased renal RAGE gene ex-
pression and MMP-2 activity in the tubules of normalDM+ ramipril RSA AGE-RSA
16 9 10
33.1 ± 3.5* 7.9 ± 1.0 7.5 ± 0.5
19.3 ± 2.7* 4.1 ± 1.5 3.9 ± 0.8
122 ± 8# 121 ± 4 118 ± 7
11.3 ± 1.1* 5.4 ± 0.3 5.4 ± 0.4
12.0 ± 1.7* 4.3 ± 1.0 4.4 ± 0.6
13.0 ± 6.8$ 1.0 ± 0.4 1.3 ± 0.5
vanced glycation end product-modified RSA, HbA1c glycated hemoglobin, BP
rate, UAE urinary albumin excretion.
Figure 1 MMP-2 activity, AGE accumulation and RAGE expression in the renal tubules of diabetic or AGE-RSA-infused rats. (A) MMP-2
activity in 32-week Ctrl or diabetic renal tubules with or without ramipril treatment was determined by gelatin zymography (n = 4). (B) AGE protein
levels in 32-week Ctrl or diabetic renal tubules with or without ramipril treatment were evaluated by enzyme-linked immunosorbent assay for
carboxymethyllisine (n = 7). (C) RAGE protein expression in 32-week Ctrl or diabetic renal tubules with or without ramipril treatment was determined
by western blot. Data were normalized by the intensity of α-tubulin bands. (n= 4). (D) RAGE gene expression in total kidney cortex of AGE-RSA- or
RSA-infused rats was evaluated by quantitative real-time RT-PCR (n = 7). (E) MMP-2 activity in the tubules of AGE-RSA- or RSA-infused rats
was determined by gelatin zymography (n = 4). Data are shown as mean ± SEM.
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and ROS generation in RPTCs, which were also sup-
pressed by ramiprilat; and (5) inhibition of NF-κB activa-
tion by BAY11-7082 blocked the MMP-2 activity or
gene expression in AGE- or Ang II-exposed RPTCs,
respectively.
In this study, ramipril decreased the AGE accumula-
tion and RAGE expression in the renal tubules ofdiabetic rats. We have previously shown that there could
exist the crosstalk between AGE-RAGE axis and RAS in
the pathogenesis of DN [14]. Indeed, irbesartan, an
AT1R blocker, inhibited the AGE-induced apoptotic cell
death and inflammatory and fibrotic reactions in human
PTCs by reducing ROS generation via suppression of
RAGE expression [29] (AGE-RAGE→RAS). Further-
more, AGE elicited mesangial cell hypertrophy by inducing
Figure 2 MMP-2 activity and gene expression, and intracellular ROS generation in RPTCs. (A, B) RPTCs were stimulated with 100 μg/ml
AGE-BSA or non-glycated BSA with or without 10−7 M ramiprilat or 100 nM BAY11-7082 for 48 hr, and MMP-2 activity in the supernatant was
determined by gelatin zymography (n = 4). (C) Intracellular ROS generation in RPTCs. Cells were stimulated with 100 μg/ml AGE-BSA or BSA with
or without 10−7 M ramiprilat for 24 hr, then the intracellular ROS generation in RPTCs was evaluated using fluorescent probe 10 μM CM-H2DCFDA.
(D) Effects of Ang II on MMP-2 gene expression in RPTCs. The cells were stimulated with 10−6 M Ang II with or without 100 nM BAY11-7082 for 24 hr
and MMP-2 gene expression was evaluated by quantitative real-time RT-PCR (n = 6). Data are shown as mean ± SEM.
Fukami et al. Diabetology & Metabolic Syndrome 2014, 6:86 Page 6 of 9
http://www.dmsjournal.com/content/6/1/86Ang II production, which was also blocked by candesartan,
other type of AT1R blocker [28] (AGE-RAGE→ RAS). In
addition, Ang II infusion increased RAGE expression in
retinas via ROS generation [43] (RAS→ AGE-RAGE).
Consistent with these findings, treatment with low-
dose valsartan, an AT1R antagonist, decreased serum
AGE levels in association with reduced oxidative stress
generation in type-2 diabetic patients [44] (RAS→
AGE-RAGE). Therefore, ramipril could inhibit the AGE-
RAGE system by suppression the RAS (Figure 3). Engage-
ment of RAGE with AGE stimulates ROS generation,
which could promote the formation and accumulation of
AGE and subsequent RAGE expression, thereby making a
vicious cycle between RAGE-downstream signaling path-
ways and AGE formation in a variety of cells [45,46].Therefore, it is also conceivable that ramipril could break
the vicious cycle between AGE and RAGE downstream
pathway by blocking the crosstalk between the RAS and
AGE-RAGE via inhibition of ROS generation (Figure 3).
In our in vitro experiment, ramiprilat completely inhibited
AGE-elicited ROS generation in RPTCs, which could sup-
port our speculation.
In our study, we demonstrated that RAS inhibition by
ramipril suppressed diabetes or AGE-induced MMP-2
activation in vivo and vitro. It has been reported that
AGE-RAGE interaction induces MMP-2 expression and
activation in several cell lines [47,48]. The interaction of
AGE-modified amyloid β and RAGE has been shown to
induce MMP-2 expression and vascular inflammatory
stress in brain endothelial cells [47]. MMP-2 activity in
Figure 3 Possible mechanisms involved in diabetes-elicited tubular MMP-2 activation via AGE-RAGE-RAS axis in diabetic nephropathy.
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creased, which was inhibited by the administration with
soluble RAGE, acting as a decoy receptor for AGE [48].
Further, increased vascular ROS generation and NF-κB
activation also promote MMP-2 activity in rat model of
renovascular hypertension [49]. In our present study,
AGE-induced MMP-2 activation was inhibited by the
blockade of NF-κB, thus suggesting that AGE-RAGE-
mediated ROS generation might induce MMP-2 activa-
tion via NF-κB. In addition, Ang II-induced MMP-2 ex-
pression was completely suppressed by the inhibition of
NF-κB in RPTCs as well. These observations suggest
that AGE-RAGE axis might stimulate Ang II generation,
which could evoke the ROS-NF-κB signaling pathway,
thereby being implicated in the tubular MMP-2 activa-
tion in diabetes.
It has been shown that decreased glomerular MMP-2
activity is associated with increased mesangial ECM ac-
cumulation and glomerular sclerosis in DN [50]. How-
ever, there is still controversy about the role of MMP-2
in DN. It is reported that the increased MMP-2 activa-
tion in tubules was involved in the development and
progression of tubulointerstitial injury [51]. Further-
more, we have recently found that serum MMP-2 levels
were positively associated with proteinuria and inversely
correlated with estimated GFR in patients with chronickidney disease [19]. These observations further support
the concept that ramipril might inhibit AGE-RAGE axis,
which could slow down the development and progres-
sion of tubulointerstitial injury by reducing albuminuria
in DN via suppression of MMP-2.
Limitations
We performed experiments in Figure 2A and B, separ-
ately. This is a reason why two gels looked slightly differ-
ent and the fold increase in active MMP-2 after AGE is
lower in Figure 2B in respect to Figure 2A. However,
there was no statistically significant difference of the in-
crease of active MMP-2 after AGE treatment between
Figure 2A and B experiments (p = 0.11). Although the
increase of ROS generation in RPTCs stimulated with
AGE versus BSA was modest, we found here that (1)
ramipril significantly suppressed the AGE-induced MMP-
2 activation and ROS generation in RPTCs and (2) inhib-
ition of NF-κB by BAY11-7082 completely inhibited the
increase of active MMP-2 in AGE-exposed cells. These
findings suggest the biological significance of modest ROS
generation in the AGE-signaling.
Conclusions
In this study, we found that MMP-2 activity, AGE and
RAGE expressions were increased in renal tubules of
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treatment with ramipril. Further, AGE infusion induced
tubular MMP-2 activation and RAGE gene expression in
rats. Ramiprilat inhibited the AGE-induced MMP-2 acti-
vation or reactive oxygen species generation in RPTCs.
These findings suggest the involvement of AGE-RAGE-
induced, RAS-mediated MMP-2 activation in experi-
mental DN. Blockade of AGE-RAGE axis by ramipril may
protect against DN partly via suppression of MMP-2.
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